Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
See our latest analysis for Amicus Therapeutics. Zooming out, Amicus's recent surge sits on top of a solid run, with the latest share price at $14.25 and both its year to date share price return and one year total shareholder return indicating momentum is building, not fading. If Amicus's move has you thinking more broadly about biotech, this could be a good moment to explore other potential ideas across healthcare stocks With shares now trading just below analyst targets but still screening as materially undervalued on some intrinsic measures, the key question is whether Amicus remains a misunderstood growth story or if the market is already pricing in its future gains. With the most followed narrative putting fair value ahead of the recent 14.25 dollars close, the spotlight turns to what assumptions are driving that gap. The company's pathway to near-term GAAP profitability, supported by disciplined operating expense management and a high gross margin profile, lays the fo
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.MarketBeat
- Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.MarketBeat
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/23/25 - Form 4
- 12/19/25 - Form 144
- 12/19/25 - Form DEFA14A
- FOLD's page on the SEC website